......SMARTEST Trial......

Status Recruiting

Clinical Trial Summary

The SMARTEST trial is a phase II non-blinded randomized trial designed to evaluate the benefit of low dose cyclophosphamide in sequential combination with sub-ablative radiation (Arm A) versus sub-ablative radiation alone (Arm B) before surgery as well as the safety and efficacy of consolidation tremelimumab-durvalumab for eligible patients after surgery in both arms.

Clinical Trial Description

This study has two parts. In the first part of the study the investigators are exploring the benefit of using low dose Cyclophosphamide in combination with low dose radiation before surgery and in the second part of the study the investigators are exploring safety and efficacy of using a combination of immunotherapy drugs, tremelimumab-durvalumab, after surgery. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05380713
Study type	Interventional
Source	University Health Network, Toronto
Contact	Marc de Perrot, MD, MSc
Phone	416 340-5549
Email	marc.deperrot@uhn.ca
Status	Recruiting
Phase	Phase 2
Start date	May 3, 2022
Completion date	October 30, 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06057935` - A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma	Phase 2
Completed	`NCT02519049` - 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)
Recruiting	`NCT04104776` - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas	Phase 1/Phase 2
Recruiting	`NCT05429866` - Immunological Variables Associated to ICI Toxicity in Cancer Patients	Phase 2
Recruiting	`NCT04981119` - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Terminated	`NCT02357147` - Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)	Phase 2
Recruiting	`NCT06281860` - Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration	Phase 1
Completed	`NCT02303899` - Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma	Phase 2
Recruiting	`NCT05568680` - SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma	Phase 1
Recruiting	`NCT06299163` - NM32-2668 in Adult Patients With Selected Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT03502746` - Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma	Phase 2
Active, not recruiting	`NCT05451849` - A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT06251310` - SW-682 in Advanced Solid Tumors	Phase 1
Recruiting	`NCT05944237` - HTL0039732 in Participants With Advanced Solid Tumours	Phase 1/Phase 2
Active, not recruiting	`NCT05455424` - Niraparib Efficacy in Patient With Unresectable Mesothelioma	Phase 2
Recruiting	`NCT05324436` - A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
Active, not recruiting	`NCT03654833` - Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma	Phase 2
Recruiting	`NCT05136677` - A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants	Phase 2
Not yet recruiting	`NCT05698238` - Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours	Phase 1
Not yet recruiting	`NCT05188859` - First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma	Phase 2